ATRACURIUM BESYLATE

First approved in 1983

Description
Sources: http://www.sagentpharma.com/wp-content/uploads/2015/04/Atracurium-Besylate_PI.pdf
Curator's Comment:: description was created based on several sources, including: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5176be07-3121-49fb-9eb9-638903753a31 | https://www.drugs.com/monograph/atracurium-besylate.html | http://www.wikidoc.org/index.php/Atracurium

Atracurium is an intermediate-duration, nondepolarizing, skeletal muscle relaxant for intravenous administration. It is used, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Most adverse reactions were suggestive of histamine release. Common side effects include flushing of the skin and low blood pressure. Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscle-type nicotinic acetylcholine receptor 64 Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19417616	Inhibitor 7728		169.5 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Skeletal muscle relaxation 17 Sources: http://www.sagentpharma.com/wp-content/uploads/2015/04/Atracurium-Besylate_PI.pdf	Palliative		Approved 8043	ATRACURIUM BESYLATE Approved Use Atracurium Besylate Injection, USP is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Launch Date 8.6918398E11

PubMed

Title	Date	PubMed
[Establishment of a hypothermic dog model to investigate airway rewarming].	2006 Aug	21158096
Dynamic encoding of natural luminance sequences by LGN bursts.	2006 Jul	16756389
Timing precision in population coding of natural scenes in the early visual system.	2008 Dec 16	19090624
Modulation of temporal precision in thalamic population responses to natural visual stimuli.	2010	21151356
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
Comparison between Culture Conditions Improving Growth and Differentiation of Blood and Bone Marrow Cells Committed to the Endothelial Cell Lineage.	2010 Feb 6	21406067
Cisatracurium in different doses versus atracurium during general anesthesia for abdominal surgery.	2010 Sep	21189851
Wound contraction and macro-deformation during negative pressure therapy of sternotomy wounds.	2010 Sep 30	20920290

Patents

Sample Use Guides

In Vivo Use Guide

An atracurium besylate dose of 0.4 to 0.5 mg/kg (1.7 to 2.2 times the ED95), given as an intravenous bolus injection, is the recommended initial dose for most patients. Maximum neuromuscular block achieved approximately 3 to 5 minutes after injection.

Route of Administration: Intravenous

In Vitro Use Guide

Exposure of isolated rat hepatocytes to atracurium produced cellular damage evidenced by extrusion of an intracellular enzyme, lactate dehydrogenase (LDH), into the incubation medium. Leakage of LDH was directly related to the concentration of atracurium in the medium (250 to 800 microM). When atracurium was added to the medium and the medium immediately added to hepatocytes, the leakage of LDH increased as the concentration of atracurium increased (P < 0.001 for the comparison with cells not exposed to atracurium).

Substance Class	Mixture Created by `admin` on `Fri Jun 25 21:04:52 UTC 2021` Edited by `admin` on `Fri Jun 25 21:04:52 UTC 2021`
Record UNII	40AX66P76P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ATRACURIUM BESYLATE

Official Name

English

ISOQUINOLINIUM, 2,2'-(1,5-PENTANEDIYLBIS(OXY(3-OXO-3,1-PROPANEDIYL)))BIS(1-((3,4-DIMETHOXYPHENYL)METHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-, (1R,2R,1'R,2'R)- BISBENZENESULFONATE

Common Name

English

NSC-760047

Code

English

(1R,2R,1'R,2'R)-2,2'-(PENTANE-1,5-DIYLBIS(OXY(3-OXOPROPANE-3,1-DIYL)))BIS(1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXY-2-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINIUM) BISBENZENESULFONATE

Common Name

English

ATRACURIUM BESYLATE [MI]

Common Name

English

ATRACURIUM BESILATE

Official Name

English

ATRACURIUM BESYLATE [USAN]

Common Name

English

TRACRIUM

Brand Name

English

ATRACURIUM BESYLATE [VANDF]

Common Name

English

ATRACURIUM BESYLATE [USP-RS]

Common Name

English

ATRACURIUM BESILATE [INN]

Common Name

English

2-(2-CARBOXYETHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-1-VERATRYLISOQUINOLINIUM BENZENESULFONATE, PENTAMETHYLENE ESTER

Common Name

English

BW-33A

Code

English

ATRACURIUM DIBESYLATE

Common Name

English

WELLCOME 33-A-74

Code

English

ATRACURIUM BESYLATE [ORANGE BOOK]

Common Name

English

BW 33A

Code

English

ATRACURIUM BESILATE [MART.]

Common Name

English

ATRACURIUM BESILATE [WHO-DD]

Common Name

English

ATRACURIUM BESYLATE [USP MONOGRAPH]

Common Name

English

ATRACURIUM BESILATE [EP MONOGRAPH]

Common Name

English

ISOQUINOLINIUM, 2,2'-(1,5-PENTANEDIYLBIS(OXY(3-OXO-3,1-PROPANEDIYL)))BIS(1-((3,4-DIMETHOXYPHENYL)METHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-, DIBENZENESULFONATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29696